Triple-Negative Breast Cancer

Obesity is a risk factor for cancer recurrence in resected hormone-sensitive breast cancer patients undergoing adjuvant chemotherapy with aromatase inhibitors, according to a recent study. Aromatase inhibitors (AIs) are extensively used for treating hormone-sensitive breast cancer (BC). In post-menopause, estrogen is mainly formed in the adipose tissue via aromatase-mediated androgen conversion, which might impair the...

Pembrolizumab plus chemotherapy significantly improves survival in advanced triple-negative breast cancer expressing programmed death ligand 1, with a combined positive score of 10 or more compared to chemotherapy alone, according to a phase 3 trial. Triple-negative breast cancer (TNBC) lacks the expression of estrogen and progesterone receptors and involves overexpression of human epidermal growth factor...

Neoadjuvant chemotherapy in combination with nab-paclitaxel and pembrolizumab shows promising pathological complete response rates. Pembrolizumab (pembro) is the only approved immune checkpoint inhibitor for the neoadjuvant treatment of early triple-negative breast cancer (TNBC). It was introduced in combination with carboplatinum/paclitaxel and anthracycline/cyclophosphamide chemotherapy. Nab-paclitaxel (nP), although not approved, is also effective in TNBC.  A study...

Episode 1: Promoting Breast Health Equity   With guest Laura Crandon, Founder and President of Touch4Life   Transcript: [00:00] LC: “So really to take what some would call a tragedy given my metastatic condition and take that and turn it into a triumph so other people can learn from what I’ve been through.” LW: Hello,...

Clinical disparities are apparent in aggressive triple-negative breast cancer based on age and ethnicity. A recent study identifies unique epigenetic differences in triple-negative breast cancer tumors among younger African American women, suggesting potential clinical implications for diagnostics and treatment approaches. Younger African American women with triple-negative breast cancer exhibit distinct DNA methylation profiles. The unique...

Research reveals potential biological factors contributing to racial disparities in breast cancer mortality rates. MicroRNA-510-5p’s interaction with the scaffolding protein caveolin-1, specifically, could drive aggressive tumor growth and highlight potential reasons behind racial disparities in breast cancer outcomes. miR-510-5p’s regulation of caveolin-1 in fibroblasts potentially fuels aggressive tumor growth. Black women with breast cancer show...

Staff Writer: Andre McGowan A retrospective study found that axillary ultrasound falsely predicted nodal response to neoadjuvant systemic treatment in approximately half of node-positive breast cancer patients, which may result in the overtreatment of breast cancer patients. However, the interpretation of axillary ultrasound in luminal human epidermal growth factor receptor 2 negative cancer is useful...

This review examines tumor biology, genetics, physical and lifestyle variables, hormone metabolism, and therapeutic obstacles that contribute to African American women’s increased rate of triple-negative breast cancer. It emphasizes the need for more research and better oncology care for African American women. Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 20% of...

The FDA has granted accelerated approval to Immunomedics’ Trodelvy (sacituzumab govitecan-hziy), the first antibody-drug conjugate that targets the Trop-2 antigen. Trodelvy is indicated for treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC). Chemotherapy has been the standard treatment for TNBC, and patients who take Trodelvy must have received at least 2 previous therapies for the cancer. Further clinical...